At a glance
- Originator Abbott Laboratories
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors; Immunosuppressants; Transforming growth factor beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Feb 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 11 Dec 1998 Preclinical development for Cancer in USA (Unknown route)